NZ234647A - Oral pharmaceutical compositions containing n-acetyl cysteine and tris(hydroxymethyl)aminomethane - Google Patents

Oral pharmaceutical compositions containing n-acetyl cysteine and tris(hydroxymethyl)aminomethane

Info

Publication number
NZ234647A
NZ234647A NZ234647A NZ23464790A NZ234647A NZ 234647 A NZ234647 A NZ 234647A NZ 234647 A NZ234647 A NZ 234647A NZ 23464790 A NZ23464790 A NZ 23464790A NZ 234647 A NZ234647 A NZ 234647A
Authority
NZ
New Zealand
Prior art keywords
nac
tham
group
aminomethane
ratio
Prior art date
Application number
NZ234647A
Other languages
English (en)
Inventor
Angelo Carenzi
Dario Chiarino
Antonio Longo
Original Assignee
Zambon Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zambon Spa filed Critical Zambon Spa
Publication of NZ234647A publication Critical patent/NZ234647A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ234647A 1989-07-27 1990-07-25 Oral pharmaceutical compositions containing n-acetyl cysteine and tris(hydroxymethyl)aminomethane NZ234647A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT8921339A IT1231012B (it) 1989-07-27 1989-07-27 Composizione farmaceutica per uso orale contenente nac.

Publications (1)

Publication Number Publication Date
NZ234647A true NZ234647A (en) 1992-02-25

Family

ID=11180335

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ234647A NZ234647A (en) 1989-07-27 1990-07-25 Oral pharmaceutical compositions containing n-acetyl cysteine and tris(hydroxymethyl)aminomethane

Country Status (20)

Country Link
US (1) US5080906A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPH0399012A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR910002438A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU625925B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE1003188A4 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2021808A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH (1) CH680190A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE4023774A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK177890A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI903759A7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2650503B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB2234171B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR900100569A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE902627A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL95158A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IT (1) IT1231012B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL9001714A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ234647A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SE (1) SE9002500L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA905861B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580577A (en) * 1990-01-11 1996-12-03 Herzenberg; Leonard A. Method of treating the symptoms of human rhinovirus infection
US5286480A (en) * 1992-06-29 1994-02-15 The Procter & Gamble Company Use of N-acetylated amino acid complexes in oral care compositions
IT1256616B (it) * 1992-12-02 1995-12-12 Zambon Spa Sciroppo contenente n-acetil-cisteina
GB9226729D0 (en) * 1992-12-22 1993-02-17 Wellcome Found Therapeutic combination
US5637616A (en) * 1993-06-18 1997-06-10 Arcturus Pharmaceutical Corporation Method for treating diseases mediated by proteases
BE1007926A3 (fr) * 1994-01-31 1995-11-21 Zambon Int Pharma Composition pharmaceutique contenant de la n-acetyl-cysteine.
US6896899B2 (en) * 1996-12-31 2005-05-24 Antioxidant Pharmaceuticals Corp. Pharmaceutical preparations of glutathione and methods of administration thereof
US6350467B1 (en) 1996-12-31 2002-02-26 Antioxidant Pharmaceuticals Corp. Pharmaceutical preparations of glutathione and methods of administration thereof
FR2803720B1 (fr) 2000-01-18 2004-10-22 Roquette Freres Lozenges a base de dextrose et leur procede de fabrication
US6114387A (en) * 2000-02-16 2000-09-05 Cutler; Paul Pharmaceutical composition for oral administration of chelating agents
US6632459B2 (en) * 2000-12-11 2003-10-14 Nutricia N.V. Chlorogenic acid and an analog thereof for immune system stimulation
US20030162732A1 (en) * 2001-07-05 2003-08-28 Astion Development A/S Combination of aminosugars and cysteine or cysteine derivatives
US20090035260A1 (en) * 2002-07-29 2009-02-05 Therapicon Srl Enhanced nasal composition of active peptide
ITMI20021881A1 (it) * 2002-09-04 2004-03-05 Zambon Spa Composizioni farmaceutiche per il trattamento di infezioni da patogeni dell'apparato urinario.
US20050008699A1 (en) * 2003-07-11 2005-01-13 Fred Wehling Effervescent glucosamine composition
ITMI20040235A1 (it) * 2004-02-13 2004-05-13 Therapicon Srl Preparazione farmaceutica per il cavo orale
KR20050104152A (ko) * 2004-04-28 2005-11-02 최승호 경구용 약물의 흡수를 증진하는 약제학적 조성물
US20090197956A1 (en) * 2008-02-04 2009-08-06 Arbor Pharmaceuticals, Inc. Treatment of acute otitis media with xylitol and n-acetylcysteine
TR200900882A2 (tr) 2009-02-05 2010-08-23 Bi̇lgi̇ç Mahmut Tadı ve kokusu maskelenmiş, bıyoyararlanımı yüksek farmasotık bileşimler.
LT3554491T (lt) * 2016-12-15 2023-05-25 Zambon S.P.A. N-acetilcisteinas, skirtas naudoti kaip antibakterinis agentas
WO2020021324A1 (en) * 2018-07-27 2020-01-30 I.C.F. Srl Compositions for the prevention and treatment of cutaneous affections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4081534A (en) * 1973-09-11 1978-03-28 Burroughs Wellcome Co. Amino purine nucleosides as autoimmune suppressant agents
US4877612A (en) * 1985-05-20 1989-10-31 Frank M. Berger Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process
CH667590A5 (it) * 1986-07-24 1988-10-31 Inpharzam Int Sa Composizione farmaceutica effervescente idrosolubile contenente n-acetil-cisteina. .
US4894225A (en) * 1987-03-02 1990-01-16 Cetus Corporation Combination therapy using antitumor immunotoxins with tumor necrosis factor
JPS63290824A (ja) * 1987-05-22 1988-11-28 Sumitomo Chem Co Ltd ウイルス感染症治療剤
IT1217445B (it) * 1988-04-29 1990-03-22 Altergon Sa Composizione farmaceutiche orosolubili contenti acetilcisteina

Also Published As

Publication number Publication date
CA2021808A1 (en) 1991-01-28
GB9016256D0 (en) 1990-09-12
US5080906A (en) 1992-01-14
FI903759A7 (fi) 1991-01-28
IE902627A1 (en) 1991-02-27
KR910002438A (ko) 1991-02-25
GB2234171A (en) 1991-01-30
DE4023774A1 (de) 1991-01-31
FR2650503A1 (fr) 1991-02-08
GB2234171B (en) 1993-11-10
BE1003188A4 (fr) 1992-01-07
IL95158A0 (en) 1991-06-10
DK177890D0 (da) 1990-07-26
GR900100569A (el) 1991-12-10
AU625925B2 (en) 1992-07-16
AU5993590A (en) 1991-01-31
IT1231012B (it) 1991-11-08
FR2650503B1 (fr) 1992-05-29
FI903759A0 (fi) 1990-07-27
ZA905861B (en) 1991-07-31
SE9002500L (sv) 1991-01-28
CH680190A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1992-07-15
JPH0399012A (ja) 1991-04-24
IT8921339A0 (it) 1989-07-27
DK177890A (da) 1991-01-28
SE9002500D0 (sv) 1990-07-26
NL9001714A (nl) 1991-02-18

Similar Documents

Publication Publication Date Title
NZ234647A (en) Oral pharmaceutical compositions containing n-acetyl cysteine and tris(hydroxymethyl)aminomethane
Spano et al. Procedure for the simultaneous determination of dopamine, 3-methoxy-4-hydroxyphenylacetic acid, and 3, 4-dihydroxyphenylacetic acid in brain
Burns et al. The biotransformation of ethyl biscoumacetate (Tromexan) in man, rabbit and dog
Toon et al. Metabolic fate of phenprocoumon in humans
Taylor et al. Tissue distribution and biliary excretion of prostacyclin metabolites in the rat.
KR930702965A (ko) 생체이용성이 개선된 프로부콜 함유 제약 조성물
Napier et al. Neocarzinostatin chromophore. Assignment of spectral properties and structural requirements for binding to DNA.
Loewen et al. High-performance liquid chromatographic method for the simultaneous quantitation of diflunisal and its glucuronide and sulfate conjugates in human urine
PT88015B (pt) Processo para a preparacao de solucoes nao aquosas de cloridrato de doxorubicina
Hegarty et al. Jejunal water and electrolyte secretion induced by L-arginine in man.
JP2001316265A (ja) オザグレルナトリウム含有注射液およびその安定化方法
Baselt et al. Biliary and urinary elimination of methadone and its metabolites in the rat
Steinetz et al. Influence of Vehicle of Administration on Intestinal Absorption, Fat Storage, and Biological Activity of Ethynylestradiol (EE) and its 3-Cyclopentyl Ethejr (EEGPE) in Rats
SEKIKAWA et al. Apparent intramolecular acyl migration and hydrolysis of furosemide glucuronide in aqueous solution
Wood Jr et al. 1-O-Benzoyl-α-D-talopyranose
CN103159720B (zh) 8-表-异穿心莲内酯-19-硫酸酯化物、制备方法及其制备药物用途
Belissa et al. Liquid chromatography–tandem mass spectrometry for simultaneous determination of ticarcillin and vancomycin in presence of degradation products. Application to the chemical stability monitoring of ticarcillin-vancomycin solutions
CN116283533B (zh) 具有nlrp3抑制活性的鸡脚参酮a及其衍生物与应用
Haginaka et al. Chromatographic analysis and pharmacokinetic investigation of cephaloglycin and its metabolites in man
JPS62265226A (ja) 経口投与用製剤
CN104119254B (zh) 7-去氢-穿心莲内酯-17-磺酸-16-羧酸或其盐、制备方法及其制备药物用途
US2357172A (en) Mono-glycosides of 2-methyl-1,4-naphthohydroquinone
PT91383B (pt) Processo para a preparacao do acido (5r,6s)-2-carbamoiloximetil-6-{(1r)-hidroxi-etil}-2-penem-3-carboxilico sob a forma cristalina e de composicoes farmaceuticas que o contem
MURPHY et al. METABOLISM OF PROPIONYL ERYTHROMYCIN LAURYL SU LFATE: II. Fate of the Lauryl Sulfate Moiety in the Rat and Man
CN104119253B (zh) 一种穿心莲内酯衍生物的药物组合物及其制备方法与用途